drugset / Trial / NCT05286931

SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection

NCT05286931

Recruiting 1800 enrolled University of Washington
NaSingle-groupOpen-labelOther

Summary

This study aims to test the effectiveness of using of SpeeDx Resistance Plus assay to guide treatment of Neisseria gonorrhoeae (Ng) in a sexual health clinic setting.

Timeline

Start
2022-03-03
Primary completion
2025-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ciprofloxacin Small molecule 500 mg Oral

Indications